TaBlitz

𝐉𝐨𝐢𝐧 𝐃𝐫. 𝐓𝐚𝐁𝐥𝐢𝐭𝐳 𝐋𝐢𝐯𝐞 𝐓𝐨𝐦𝐨𝐨𝐫𝐫𝐨𝐰!

Every month, we take one real formulation or production problem—sticking, picking, capping, lamination, scale-up breakdowns—and open it up.

𝘙𝘦𝘢𝘭 𝘧𝘰𝘰𝘵𝘢𝘨𝘦. 𝘙𝘦𝘢𝘭 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴. 𝘙𝘦𝘢𝘭 𝘢𝘯𝘴𝘸𝘦𝘳𝘴.

You’ll see what’s happening inside and outside the tablet press during compaction.
You’ll watch live TaBlitz demos tracing root cause in real time.
And you’ll hear expert insight connecting what’s happening on press to why it’s happening in your formulation.

We close every session with live Q&A—bring the question that’s been holding your batch back and get a direct answer.

🚨 1 day away — don’t miss it

Join Pharma Excipients, all4nutra.com, Dr. TaBlitz, and Natoli Scientific

𝗗𝗿. 𝗧𝗮𝗯𝗹𝗶𝘁𝘇 𝗟𝗶𝘃𝗲 𝗦𝗲𝘀𝘀𝗶𝗼𝗻𝘀
📅 Tuesday, Apr. 14, 2026
⏰ 10:00 AM EDT | 4:00 PM CET

Streaming live on YouTube and LinkedIn.

👉 Set your reminder and subscribe so you don’t miss it:
https://lnkd.in/erQGPcQH

𝐈𝐟 𝐲𝐨𝐮’𝐫𝐞 𝐚 𝐕𝐢𝐫𝐭𝐮𝐚𝐥 𝐃𝐫𝐮𝐠 𝐂𝐨𝐦𝐩𝐚𝐧𝐲, 𝐭𝐡𝐢𝐬 𝐜𝐚𝐫𝐨𝐮𝐬𝐞𝐥 𝐢𝐬 𝐫𝐞𝐪𝐮𝐢𝐫𝐞𝐝 𝐫𝐞𝐚𝐝𝐢𝐧𝐠.

Because this is exactly where TaBlitz fits — and why it matters.

Here’s the uncomfortable truth:

When you operate asset-light, your leverage doesn’t come from equipment.
It comes from insight.
If you're building a program without owning manufacturing, let’s talk about how to own the risk instead.

Reserve a 1-hour session and explore how predictive insight can save time, material, and cost.
The link: https://lnkd.in/gA2SrvjS

𝐕𝐢𝐫𝐭𝐮𝐚𝐥 𝐃𝐫𝐮𝐠 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐚𝐫𝐞 𝐛𝐮𝐢𝐥𝐭 𝐭𝐨 𝐨𝐩𝐞𝐫𝐚𝐭𝐞 𝐥𝐞𝐚𝐧.
But lean should never mean blind.

When you don’t own manufacturing, your leverage comes from clarity.

Clarity on your formulation.
Clarity on your risks.
Clarity on what will — and won’t — scale.

That’s where TaBlitz changes the equation.

We help VDCs move forward with:

✅ Early, material-sparing insight
✅ Physics-based formulation confidence
✅ Predictive robustness before scale-up
✅ A stronger technical position with CDMOs
✅ A cleaner, more defensible narrative for regulators and investors

This isn’t incremental value.

It’s structural risk reduction.

If you’re building lean, build informed.

Let’s talk. Demo here: https://lnkd.in/gHQCv72d

𝐌𝐨𝐬𝐭 𝐭𝐚𝐛𝐥𝐞𝐭 𝐟𝐚𝐢𝐥𝐮𝐫𝐞𝐬 𝐚𝐫𝐞𝐧’𝐭 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭.
𝐓𝐡𝐞𝐲’𝐫𝐞 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐞𝐝 𝐚𝐭 𝐭𝐡𝐞 𝐰𝐨𝐫𝐬𝐭 𝐩𝐨𝐬𝐬𝐢𝐛𝐥𝐞 𝐦𝐨𝐦𝐞𝐧𝐭.

Traditionally, failure modes show up in one of three painful ways:

🔹 During the first engineering or exhibit batch — when confidence is high and timelines are tight.
🔹 During PPQ — the most expensive moment to learn something new about your formulation.
🔹 After approval — when a new raw material lot or seasonal humidity shift quietly pushes the process outside its undocumented limits.

By the time these issues appear, the formulation is locked, the validation plan is active, and the cost of adjustment is measured in weeks — not hours.

𝐖𝐡𝐚𝐭 𝐦𝐚𝐤𝐞𝐬 𝐭𝐡𝐢𝐬 𝐞𝐬𝐩𝐞𝐜𝐢𝐚𝐥𝐥𝐲 𝐟𝐫𝐮𝐬𝐭𝐫𝐚𝐭𝐢𝐧𝐠?

In most cases, the failure wasn’t random.
It was hiding in the physics — in the micromeritics, the compaction limits, the strain-rate sensitivity, the geometry stress distribution.

It just wasn’t evaluated early enough.

The strongest teams are no longer asking,
“Did it pass?”

They’re asking,
“Where are the edges — and have we tested them?”

Because robustness isn’t proven at the center of the design space.
It’s proven at the boundaries.

And discovering those boundaries during PPQ is not a strategy — it’s a gamble.

👉 If you want to identify your formulation’s edges before engineering batches, PPQ, or post-approval variability does it for you, let’s talk.
Schedule a demo and see how predictive robustness changes the way you approach scale-up.

Schedule your demo here: https://lnkd.in/gA2SrvjS

Have you ever designed a tablet that worked perfectly on paper…
only to realize it physically couldn’t be made?

The formulation was sound.
The was in spec.
Early looked promising.

Then someone asked the question that stops projects cold:

“Will this actually fit into the tablet we’re trying to make?”

That’s when bulk density quietly takes control.

𝐖𝐡𝐲 𝐁𝐮𝐥𝐤 𝐃𝐞𝐧𝐬𝐢𝐭𝐲 𝐢𝐬 𝐊𝐞𝐲 𝐭𝐨 𝐘𝐨𝐮𝐫 𝐎𝐮𝐭𝐜𝐨𝐦𝐞

In tablet design, bulk density determines how much mass can physically enter the die before compression even begins.

When bulk density is too low:

✅ You can’t hit target tablet weight
✅ Tablet size reductions become impossible
✅ Fill depth maxes out early
✅ Scale-up flexibility disappears

And once you reach manufacturing, the formulation is locked. There’s no easy fix.

𝐖𝐡𝐲 𝐓𝐞𝐚𝐦𝐬 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐓𝐡𝐢𝐬 𝐓𝐨𝐨 𝐋𝐚𝐭𝐞

Most formulation teams don’t encounter bulk density limits until:

✅ A tablet size reduction is requested
✅ Drug load increases
✅ A new excipient lot behaves slightly differently
✅ Scale-up introduces tighter geometric constraints

At that point, the question shifts from “Is this optimal?” to
“How do we salvage this?”

That’s an expensive pivot.

𝐇𝐨𝐰 𝐓𝐚𝐁𝐥𝐢𝐭𝐳 𝐂𝐡𝐚𝐧𝐠𝐞𝐬 𝐭𝐡𝐞 𝐂𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧

TaBlitz doesn’t treat bulk density as a background data point.

It treats it as a .

By combining bulk density with:

✅ Tablet geometry
✅ Target tablet weight
✅ Tooling design
✅ Compression limits

TaBlitz answers a question most teams only ask after problems appear:

“𝐈𝐬 𝐭𝐡𝐢𝐬 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐩𝐡𝐲𝐬𝐢𝐜𝐚𝐥𝐥𝐲 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐚𝐛𝐥𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐭𝐚𝐛𝐥𝐞𝐭 𝐰𝐞 𝐰𝐚𝐧𝐭?”

Before you:

✅ Run a
✅ Consume kilos of API
✅ Redesign tooling
✅ Hit a scale-up wall

A Scenario We See All the Time

A team designs a 500 mg tablet early on. Everything works.

Later, the request comes in:

👉 Increase drug load
👉 Reduce tablet size
👉 Improve swallowability

On paper, it looks achievable.

𝐓𝐚𝐁𝐥𝐢𝐭𝐳 𝐟𝐥𝐚𝐠𝐬 𝐭𝐡𝐞 𝐢𝐬𝐬𝐮𝐞 𝐢𝐧𝐬𝐭𝐚𝐧𝐭𝐥𝐲:

At this , the cannot physically fit into the proposed tablet geometry.

Not maybe.
Not let’s try.
Cannot.

That insight alone can save months of reformulation.

𝐖𝐡𝐲 𝐓𝐡𝐢𝐬 𝐌𝐚𝐭𝐭𝐞𝐫𝐬 𝐭𝐨 #𝐅𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭𝐬

Bulk density doesn’t just affect filling.

It defines:

✅ Design flexibility
✅ Late-stage change options
✅ Scale-up success
✅ Project momentum

TaBlitz helps teams move from:

➡️ Trial-and-error
➡️ Firefighting

to:

➡️ Predictive design
➡️ Confident decision-making

𝐈𝐟 𝐲𝐨𝐮 𝐰𝐚𝐧𝐭 𝐭𝐨 𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝 𝐡𝐨𝐰 𝐛𝐮𝐥𝐤 𝐝𝐞𝐧𝐬𝐢𝐭𝐲 𝐢𝐬 𝐬𝐡𝐚𝐩𝐢𝐧𝐠 𝐲𝐨𝐮𝐫 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬 — 𝐛𝐞𝐟𝐨𝐫𝐞 𝐢𝐭 𝐥𝐢𝐦𝐢𝐭𝐬 𝐭𝐡𝐞𝐦 — 𝐬𝐜𝐡𝐞𝐝𝐮𝐥𝐞 𝐚 𝐓𝐚𝐁𝐥𝐢𝐭𝐳 𝐝𝐞𝐦𝐨 𝐚𝐧𝐝 𝐬𝐞𝐞 𝐢𝐭 𝐩𝐫𝐞𝐝𝐢𝐜𝐭𝐞𝐝, 𝐧𝐨𝐭 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐞𝐝 𝐭𝐡𝐞 𝐡𝐚𝐫𝐝 𝐰𝐚𝐲.

𝐓𝐡𝐢𝐬 𝐜𝐨𝐮𝐥𝐝 𝐛𝐞 𝐨𝐮𝐫 𝐦𝐨𝐬𝐭 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐩𝐨𝐬𝐭 𝐲𝐞𝐭.

Most teams don’t struggle with Quality by Design because the framework is wrong.
They struggle because insight arrives after the cost has already been paid—
in kilograms of API, repeated DoE cycles, and late-stage rework.

This carousel walks through a familiar pattern:
• Where development costs quietly escalate
• Why material-heavy learning is often a symptom of late insight
• How integrating predictive understanding earlier changes both science and economics

If your QbD strategy is sound but development still feels expensive, this story is for you.

👉 𝘚𝘸𝘪𝘱𝘦 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘵𝘰 𝘴𝘦𝘦 𝘩𝘰𝘸 𝘵𝘦𝘢𝘮𝘴 𝘢𝘳𝘦 𝘳𝘦𝘥𝘶𝘤𝘪𝘯𝘨 𝘤𝘰𝘴𝘵 𝘣𝘺 𝘤𝘩𝘢𝘯𝘨𝘪𝘯𝘨 𝘸𝘩𝘦𝘯 𝘵𝘩𝘦𝘺 𝘭𝘦𝘢𝘳𝘯—𝘯𝘰𝘵 𝘩𝘰𝘸 𝘮𝘶𝘤𝘩 𝘵𝘩𝘦𝘺 𝘦𝘹𝘱𝘦𝘳𝘪𝘮𝘦𝘯𝘵.

𝐁𝐨𝐨𝐤 𝐭𝐡𝐞 𝐝𝐞𝐦𝐨 𝐡𝐞𝐫𝐞: https://lnkd.in/g5UgjDYv